PHARMACYTE BIOTECH, INC. Accretion Expense
PHARMACYTE BIOTECH, INC. (PMCB) reported Accretion Expense of $0 for the 3-month period ending 2025-01-31, per its 10-Q filed 2025-03-17.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2025-03-17
- PHARMACYTE BIOTECH, INC. accretion expense for the quarter ending 2025-01-31 was $0.00.
- PHARMACYTE BIOTECH, INC. accretion expense for the quarter ending 2024-10-31 was $1.05M.
- PHARMACYTE BIOTECH, INC. accretion expense for the quarter ending 2024-07-31 was $2.15M, a 34.35% decline year-over-year.
- PHARMACYTE BIOTECH, INC. accretion expense for the quarter ending 2023-07-31 was $3.27M.
- PHARMACYTE BIOTECH, INC. accretion expense for fiscal 2024 was $15.05M.
| Period end | Accretion Expense 3 month | Accretion Expense 6 month | Accretion Expense 9 month | Accretion Expense 12 month |
|---|---|---|---|---|
| 2025-01-31 | $0.00 10-Q · filed 2025-03-17 | $1.05M derived: sum of 2 quarters · filed 2025-03-17 | $3.19M 10-Q · filed 2025-03-17 | |
| 2024-10-31 | $1.05M 10-Q · filed 2024-12-13 | $3.19M 10-Q · filed 2024-12-13 | ||
| 2024-07-31 | $2.15M 10-Q · filed 2024-09-17 | |||
| 2024-04-30 | $15.05M 10-K · filed 2024-08-13 | |||
| 2023-07-31 | $3.27M 10-Q · filed 2024-09-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |